精子蛋白 17 作为上皮性卵巢癌肿瘤标志物的有效性和预后意义：一项回顾性研究。
Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
机构信息
Department of Obstetrics & Gynecology, University of Southern California, 1450 Biggy Street, Los Angeles, CA, 90033, USA.
Norris Comprehensive Cancer Center, University of Southern California, California, Los Angeles, USA.
出版信息
BMC Cancer. 2018 Oct 11;18(1):970. doi: 10.1186/s12885-018-4880-x.
BACKGROUND
Prior small studies have shown increased expression of sperm protein 17 (Sp17) in epithelial ovarian cancer (EOC) tissue and suggest Sp17 as a potential biomarker for EOC. However, how Sp17 expression varies with histology, grade, and stage of EOC and its expression in other ovarian neoplasms has not been defined. It is unknown whether patients with EOC have elevated serum Sp17 levels or if Sp17 expression is associated with survival outcomes.
METHODS
The study included 982 patients with benign, borderline, and malignant ovarian neoplasms and normal ovary. There were 878 patients with tissue only, 39 with serum only, and 65 with matching serum and tissue. Immunohistochemical (IHC) staining with anti-Sp17 antibody was performed on tissue specimens and the intensity scored as weak, moderate, or strong. A sandwich enzyme-linked immunosorbent assay (ELISA) was performed to measure Sp17 sera concentrations.
RESULTS
Sp17 expression was most commonly seen in serous cystadenomas (83%) and serous borderline tumors (100%). Of the 773 EOC specimens, 223 (30%) expressed Sp17. Grade and histology were significantly associated with Sp17 expression among EOC specimens (p < 0.001) on both univariate and multivariable analysis, with grade 1 serous adenocarcinomas showing the highest expression (51%). Sp17 expression was limited in other benign and non-epithelial malignant neoplasms. Neither Sp17 tissue expression nor serum concentration correlated with survival outcomes. Serum concentrations were higher in patients with Sp17 tissue expression, and the highest concentrations were noted among patients with serous and clear cell adenocarcinomas.
CONCLUSIONS
Sp17 is highly expressed in benign, borderline, and low grade malignant serous ovarian neoplasms and can be quantified in serum. Sp17 expression may have diagnostic significance in this subset of patients.
背景
先前的小型研究表明，精子蛋白 17（Sp17）在卵巢上皮癌（EOC）组织中的表达增加，并提示 Sp17 可能是 EOC 的潜在生物标志物。然而，Sp17 的表达如何随 EOC 的组织学、分级和分期而变化，以及其在其他卵巢肿瘤中的表达尚未确定。尚不清楚 EOC 患者是否存在血清 Sp17 水平升高，或者 Sp17 表达是否与生存结局相关。
方法
该研究纳入了 982 例良性、交界性和恶性卵巢肿瘤及正常卵巢患者。其中 878 例患者仅接受了组织检查，39 例患者仅接受了血清检查，65 例患者接受了血清和组织匹配检查。采用抗 Sp17 抗体进行组织标本免疫组织化学（IHC）染色，并对染色强度进行评分，分为弱、中、强。采用夹心酶联免疫吸附试验（ELISA）测量 Sp17 血清浓度。
结果
Sp17 表达最常见于浆液性囊腺瘤（83%）和浆液性交界性肿瘤（100%）。在 773 例 EOC 标本中，223 例（30%）表达 Sp17。在 EOC 标本中，分级和组织学在单变量和多变量分析中均与 Sp17 表达显著相关（p<0.001），其中 1 级浆液性腺癌表达最高（51%）。Sp17 表达在其他良性和非上皮性恶性肿瘤中受到限制。无论是 Sp17 组织表达还是血清浓度均与生存结局无关。Sp17 组织表达患者的血清浓度较高，在浆液性和透明细胞腺癌患者中浓度最高。
结论
Sp17 在良性、交界性和低级别恶性浆液性卵巢肿瘤中高表达，并且可以在血清中定量。Sp17 表达在这部分患者中可能具有诊断意义。
Zotero 插件